Skip to main content
. 2006 Jun;80(11):5651–5654. doi: 10.1128/JVI.02597-05

FIG. 2.

FIG. 2.

Biochemical and immunological characterization of KoRV. (a) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of sucrose gradient-purified KoRV produced by human 293 cells with Coomassie blue staining. (b) Western blot analysis of the same material using a rat antiserum specific for KoRV p15E that recognized p15E and the precursor gp85. (c) Western blot analysis of cell lysates from human 293 cells producing KoRV from (lane 1) human 293 cells producing PERV and (lane 2) mouse NIH 3T3 cells producing MuLV and (lane 3) using a goat antiserum specific for PERV p27Gag. (d) Western blot analyses using recombinant p15E of KoRV as antigens and sera from three different rats (A, B, C) immunized with recombinant p15E (rp15E) of KoRV. (e) Neutralizing activity of rat sera (immune sera [IS]) in comparison to that of preimmune sera (PS) at a dilution of 1:8. Infection was measured as the percentage of provirus integration using real-time PCR. Results are expressed as means and standard deviations.